NextGen Healthcare, Inc.

Stock Symbol: 
Case Status: 

Ademi LLP is investigating NextGen Healthcare (Nasdaq: NXGN) for possible breaches of fiduciary duty and other violations of law in its transaction with Thoma Bravo.

In the transaction, NextGen Healthcare stockholders are expected to receive only $23.95 per share. The transaction agreement unreasonably limits competing transactions for NextGen Healthcare by imposing a significant penalty if NextGen Healthcare accepts a competing bid. NextGen Healthcare insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of NextGen Healthcare’s board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.